Clinical Trial Update: Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates the impact of epoetin alfa (erythropoietin) administered during definitive radiotherapy for cervical cancer on treatment outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Medical University of Vienna | Conditions: Cervix Cancer | Phase 3 | Status: UNKNOWN